The overexpression of osteopontin in tumor tissues has been associated with a worse prognosis in a variety of malignancies, including squamous cell carcinoma of the esophagus [14, 18] and head and neck [13], but only few studies have addressed the role of osteopontin in chemoradiotherapy resistance [19, 20], especially in ESCC. This evidence concerns the gene SPP1 and esophageal squamous cell carcinoma.